Skip to content

AbbVie opts in to develop fibrotic disease candidates with Morphic

August 25, 2020

Morphic Therapeutic (NASDAQ:MORF) announces that collaboration partner and licensee AbbVie (NYSE:ABBV) has exercised its option to develop its αvβ6 integrin inhibitors for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and additional indications.

The license covers αvβ6 integrin specific inhibitors discovered from Morphic’s proprietary MInT Platform, including the compounds MORF-720 and MORF-627.

AbbVie’s decision triggers a $20M license fee to Morphic, which will also be eligible for future development milestones and royalties on net sales of commercialized products.

Morphic received $100M upfront under the terms of their original agreement.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: